Pharmaceutical Processing World
Online/Digital
Since 1984, Pharmaceutical Processing has provided industry professionals with news, analysis and information on the cutting-edge technologies and services for the pharmaceutical, biopharmaceutical and biotech markets. From formulation to packaging to smart manufacturing, Pharmaceutical Processing World provides comprehensive coverage on the latest technologies and best practices being used in today’s marketplace.
The publication also covers analysis related to the pharmaceutical industry, including new product introductions, drug pricing and treatment trends and regulatory news.
We also publish the Big Pharma 50 feature each year, which provides insights on the largest drug companies, their R&D spending, best-selling drugs and drug-development candidate pipeline.
Pharmaceutical Processing World’s editorial focuses on the critical issues affecting the pharmaceutical manufacturing industry, ranging from outsourcing and contract development to smart manufacturing and Industry 4.0. Other topics include biologics, biopharmaceutical products and pharmaceutical innovation.
Our readers include chemical engineers, technicians, facility managers and regulatory professionals. Source
Actions
Media Outlet details
| Scope | Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesSiemens Healthineers links with Novo to advance liver fibrosis blood test
Siemens Healthineers has teamed up with the recently rebranded drugmaker Novo on a project to advance its blood test for hidden liver disease, in a bid to deliver earlier diagnoses and access to treatment.
Artis BioSolutions announces new center of excellence in Spain
Artis BioSolutions has facilities in San Diego, Boston and Balboa, Spain. [Courtesy of Artis BioSolutions] Artis BioSolutions announced the launch of its Genetics Medicines Center of Excellence in Bilbao, Spain, where it already has a facility specializing in synthetic DNA manufacturing. The company, which also has facilities in Boston and San Diego, supports genetic medicine developers with manufacturing processes.
Bristol Myers Squibb’s RazyeBio to build $173 million Indiana facility
RayzeBio, a subsidiary of Bristol Myers Squibb, announced plans to construct a new $173 million facility in Whitestown, Indiana. The 225,000-square-foot facility will be located at the Anson Industrial Park in Boone County and will manufacture radiopharmaceutical therapies (RPTs). Construction is expected to begin this year. The company currently has a 77,000-square-foot RPT supply and manufacturing facility in Indianapolis, which began operations in July 2025.
Bristol Myers Squibb to build new plant in Houston
Rendering of Bristol Myers Squibb’s planned $2.3 billion state-of-the-art manufacturing campus in Houston, Texas. [Image courtesy of BMS] Bristol Myers Squibb (NYSE:BMY) announced the selection of Houston, Texas, as the site for a new 600,000 square-foot multi-modal manufacturing campus, representing an approximately $2.3 billion investment. The campus, at Generation Park in Houston, will create nearly 500 skilled jobs, the company said.
How computer vision can improve defect detection and traceability in pharma inspection
By the engineering team at Lantern Med Digital (LMD) A pharmaceutical manufacturing worker monitors a production line. Computer vision systems can complement human inspection by flagging visible defects and preserving image-based records for review and traceability. (Image credit: Adobe Stock) Pharmaceutical manufacturing depends on repeatable inspection.
Codis completes acquisition of Catalent manufacturing plant
The Nottingham facility acquired from Catalent [Image courtesy of Codis] Codis announced today that it completed its previously announced acquisition of a UK-based manufacturing facility from Catalent. The Haverhill, England-based company agreed to acquire the oral solid dose (OSD) development and manufacturing plant in Nottingham last month.
Ratio Therapeutics raises $70M to expand manufacturing infrastructure
Ratio Therapeutics announced today that it closed a $70 million Series C financing to support its radiopharmaceutical development and manufacturing. Existing investors Duquesne Family Office and Bristol Myers Squibb participated. New investors Catalio Capital Management, Eli Lilly and Wasatch Group joined as well. Boston-based Ratio plans to use the proceeds to fund its next phase of growth.
Resilience, Lilly invest $750M in pharma, KwikPen manufacturing
[Image courtesy of Resilience/Lilly] Resilience announced today that it expanded its strategic partnership with Eli Lilly (NYSE:LLY) to increase medicine production in the U.S. The Cincinnati-based CDMO and the pharmaceutical giant first struck a partnership in 2023. Now, with $750 million invested, the companies are expanding Resilience’s advanced pharmaceutical manufacturing operations in Ohio.
OEE is not a hammer, nor is every problem a nail
Consider a common scenario: a pharmaceutical manufacturing plant has identified the equipment most critical to the success of its processes and has begun tracking overall equipment effectiveness (OEE) for those assets. Management has set an ambitious OEE metric of 95% for those critical machines, and operators and technicians are collaborating closely to make sure they hit their benchmarks. The team manages to bring all critical assets up to 95% OEE 24 hours a day, 7 days a week.
BeOne Medicines invests more than $1B to expand pharma manufacturing
The Hopewell campus [Image courtesy of BeOne Medicines] BeOne Medicines (Nasdaq:ONC) today announced the investment of $300 million to expand its U.S. manufacturing base. The expansion comes at the company’s flagship clinical and commercial-stage manufacturing and R&D center in Hopewell, New Jersey. It brings BeOne’s total U.S. manufacturing investment to more than $1 billion.